aneurysms, coronary vasospasm and thrombo-embolic phenomena may also lead to ACS in Behcet's syndrome. 2 3 Vascular endothelial cell injury and resultant endothelial dysfunction seem to play a role in the CSF leading to ACS. 1 2 We report a patient with Behcet's syndrome, and history of hypertension who had CSF presenting with severe myocardial ischemia leading to ACS. A 54-year-old woman was admitted with 2 hours of severe retrosternal chest pain and nausea. Physical showed no wall motion disturbances and an ejection fraction of 60%. The initial and follow-up cardiac enzymes were found to be within the normal range. The patient was discharged after 3 days without any complications. No optimal therapeutic approach exists for CSF except for vasodilator agents as calcium-channel blockers and/or dipyridamole, which are beneficial for microvascular dysfunction. 2 3 Videos 2 The coronary angiography revealed normal coronary arteries with marked slowing of coronary flow and delayed washout of contrast throughout lumen of left anterior descending and circumflex coronary arteries.
Videos 3
The coronary angiography revealed normal coronary arteries with marked slowing of coronary flow and delayed washout of contrast throughout lumen of right coronary artery.
Videos 1
The coronary angiography revealed normal coronary arteries with marked slowing of coronary flow and delayed washout of contrast throughout lumen of left anterior descending and circumflex coronary arteries.
Videos 4 The coronary angiography showed normal coronary artery with marked slowing down of coronary flow and delayed washout of contrast throughout lumen of left anterior descending and circumflex coronary arteries.
Learning points
▸ Coronary slow flow (CSF) is a phenomenon characterized by delayed opacification of coronary arteries in the absence of epicardial stenosis. ▸ Vascular endothelial cell injury and resultant endothelial dysfunction seem to play a role in the CSF leading to ACS. ▸ No optimal therapeutic approach exists for CSF except for vasodilator agents as calcium-channel blockers and/ or dipyridamole, which are beneficial for microvascular dysfunction.
